• Zolmitriptan 5-HT1B Research Workflows

  2026-09-16

  Build reproducible Zolmitriptan assays around receptor subtype selectivity, solvent control, and time-resolved neurovascular readouts. This guide separates evidence-based migraine and cluster headache applications from lysosomal biology insights that can improve assay design without implying an antiviral role.

• RRP Restores Lipid Metabolism in Hepatic IRI

  2026-09-16

  A 2024 Journal of Ethnopharmacology study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by rebalancing hepatocyte cholesterol metabolism. Its mechanistic model links AMPK activation to suppression of SCAP-SREBP2 cholesterol synthesis and enhancement of LXRα-dependent cholesterol efflux, providing a useful framework for lipid-injury research.

• Phosbind Acrylamide: SDS-PAGE Guide

  2026-09-15

  Phosbind Acrylamide is a phosphate-binding reagent for comparing phosphorylated and non-phosphorylated proteins through phosphorylation-dependent mobility shifts during SDS-PAGE. It is suited to protein phosphorylation analysis, particularly for targets in the 30–130 kDa range, but it should not be treated as a phosphosite-identification method or a substitute for quantitative phosphorylation assays.

• Tomivosertib: Mapping MNK–eIF4E in Glioblastoma

  2026-09-15

  Tomivosertib is a potent MNK1 inhibitor for dissecting translational control in glioblastoma. This article focuses on compartment-resolved target engagement, angiogenesis assays, and chemotherapy-response mechanisms rather than repeating general MNK biology.

• GS-441524: Mechanism, Evidence & Workflow

  2026-09-14

  GS-441524 is a nucleoside analog studied as an anti-SARS-CoV-2 nucleoside analog and intracellular precursor to an active triphosphate. Current GS-441524 antiviral research distinguishes the parent nucleoside from engineered prodrugs such as NGP-1 and uses LC–MS/MS to resolve conversion, exposure, and matrix effects.

• Chrysin, NOX2, and Ferroptosis in Dry Eye

  2026-09-14

  A 2026 study identifies NOX2-dependent ferroptosis and STING/NLRP3 inflammation as linked mechanisms of corneal epithelial injury in dry eye. Its combination of transcriptomic analysis, ocular-surface models, pathway perturbation, and oxidative-stress measurements provides a mechanistic framework for evaluating chrysin while highlighting the need for orthogonal viability and cell-death assays.

• FITC Goat Anti-Mouse IgG (H+L) Antibody Workflow

  2026-09-13

  Translate SGK1–RanBP1 spindle biology into practical mouse-oocyte imaging with a sensitive fluorescein-conjugated secondary antibody. This workflow combines stage-resolved immunofluorescence, optional flow cytometry, quantitative controls, and troubleshooting guidance for cleaner mouse IgG detection.

• Phosbind Biotin: A Smarter Phosphoprotein Workflow

  2026-09-12

  Phosbind Biotin enables sequence-independent analysis of phosphorylated proteins on PVDF membranes. This article explains how to use its dinuclear metal complex phosphate binding to test phosphorylation-dependent biology, using the PtrbZIP12 poplar drought study as a practical decision framework.

• Novobiocin Sodium: DNA Gyrase Workflow Guide

  2026-09-11

  Novobiocin Sodium enables time-resolved experiments that distinguish DNA replication arrest from DNA degradation while linking chromosome control to membrane growth and vacuole formation. This practical guide adapts the Enterococcus faecalis protoplast model into workflows for imaging, qPCR, cell-cycle analysis, and antibiotic resistance research.

• Gramine Workflow for Ferroptosis Research

  2026-09-11

  Gramine provides a mechanism-led route from TNBC growth inhibition to CUL3–MTDH pathway validation and ferroptosis confirmation. This practical workflow combines fresh-solution handling, dose optimization, orthogonal assays, and rescue experiments for more interpretable cancer biology research.

• Tin Mesoporphyrin IX: HO Assay Workflow Guide

  2026-09-10

  Tin Mesoporphyrin IX enables controlled interrogation of heme oxygenase activity in cell-free, metabolic, and virology models. This guide translates its nanomolar biochemical potency into practical assay design while showing how HO-1 and ROS measurements can be paired without overinterpreting antiviral or translational results.

• Tetrahydromagnolol in CB2 Signaling Workflows

  2026-09-10

  Tetrahydromagnolol combines potent peripheral CB2 receptor agonism with GPR55 antagonism, enabling pathway-resolved cannabinoid receptor research rather than single-endpoint screening. This workflow guide shows how to connect receptor pharmacology with inflammatory, analgesic, migration, and GPCR-to-cytoskeleton assays while separating established evidence from testable hypotheses.

• Tomivosertib Suppresses Human DRG Ectopic Activity

  2026-09-09

  The reference study provides direct ex vivo evidence that MNK inhibition with tomivosertib rapidly and reversibly suppresses spontaneous activity in human dorsal root ganglion neurons obtained from patients with radiculopathy. Its combination of electrophysiology and rapid eIF4E target engagement strengthens the translational rationale for MNK-directed neuropathic pain research while leaving clinical efficacy and cell-selectivity questions unresolved.

• LY294002: PI3K/Akt/mTOR Research Guide

  2026-09-09

  LY294002 is a cell-permeable, reversible class I PI3K inhibitor that suppresses PI3K/Akt/mTOR signaling through ATP-site binding. Its biochemical activity, autophagy effects, apoptosis induction in cancer cells, formulation limits, and ovarian carcinoma research applications support controlled mechanistic experiments rather than direct clinical translation.

• 15-PGDH Inhibition Supports Muscle Repair During Weight Loss

  2026-09-08

  A 2026 PNAS study identifies 15-PGDH inhibition as a strategy for improving skeletal muscle regeneration and force recovery during semaglutide-associated weight loss in obese mice. The work shows that combining a 15-PGDH inhibitor with semaglutide can enhance muscle stem cell activity and regenerated myofiber growth without reducing the drug’s weight-loss effect.

8450 records 1/564 page Next 12345 下5页 Last page